Breaking News, Collaborations & Alliances

Plasticell, LambdaGen Partner to Develop Allogeneic Cancer Immunotherapies

LambdaGen to produce iPSC lines that enhance anti-tumor activity and Plasticell will use its combinatorial screening technology to develop optimal protocols.

Plasticell Ltd, a developer of stem cell technologies and advanced therapies, has entered into a strategic collaboration with Singapore-based LambdaGen. The two companies will exploit genome editing technologies based on synthetic lambda integrases that allow specific insertion of large gene cassettes into the human genome. The partnership is in part financed by a EUREKA GlobalStars competitive grant. The funding has been awarded to enable the two organizations to carry out a project – valued...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters